Clinical Trials
35 trialsMK-5684-004
Merck Sharp & Dohme LLC
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited
MEVPRO-3
Pfizer
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Amgen
PREDICT
Alliance for Clinical Trials in Oncology
rechARge
Celgene
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Novartis
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
M.D. Anderson Cancer Center
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
PRO-MIND
Ankara Etlik City Hospital
TALENT
Prostate Cancer Clinical Trials Consortium
AMX-500
Vir Biotechnology, Inc.
DIVINE
Mayo Clinic
TRIPLE-SWITCH
Canadian Cancer Trials Group
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Inc
Double-DARE
Bayer
VA STARPORT
VA Office of Research and Development
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
National Institutes of Health Clinical Center (CC)
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
University of Chicago
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
AcTFirst
Novartis
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Astellas Pharma Inc
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
The COSMYC Trial (COmbined Suppression of MYC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
ORIC Pharmaceuticals
PSA-DEEP02
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
TEAM PC
Fundacion Oncosur
ANZadapt
Leiden University Medical Center
DIRECT
University Health Network, Toronto
ECHOS
Santa Chiara Hospital
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Portland VA Medical Center